|
🐜
|
Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression
10 auth.
Z. Brkić,
N. Maria,
C. V. van Helden-Meeuwsen,
J. P. Van de Merwe,
P. V. van Daele,
V. Dalm,
...
M. Wildenberg,
W. Beumer,
H. Drexhage,
M. Versnel
|
8 |
2012 |
8
🐜
|
|
🐬
|
Systemic increase in type I interferon activity in Sjögren's syndrome: A putative role for plasmacytoid dendritic cells
M. Wildenberg,
C. V. van Helden-Meeuwsen,
J. P. Van de Merwe,
H. Drexhage,
M. Versnel
|
7 |
2008 |
7
🐬
|
|
🐜
|
The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis
16 auth.
Z. Brkić,
L. van Bon,
M. Cossu,
C. V. van Helden-Meeuwsen,
M. Vonk,
H. Knaapen,
W. B. van den Berg,
V. Dalm,
P. V. van Daele,
A. Severino,
...
N. Maria,
Samara Guillen,
W. Dik,
L. Beretta,
M. Versnel,
T. Radstake
|
7 |
2015 |
7
🐜
|
|
🐜
|
MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome
10 auth.
N. Maria,
Z. Brkić,
M. Waris,
C. V. van Helden-Meeuwsen,
K. Heezen,
J. P. Van de Merwe,
...
P. V. van Daele,
V. Dalm,
H. Drexhage,
M. Versnel
|
6 |
2013 |
6
🐜
|
|
🐜
|
Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity
14 auth.
I. Bodewes,
S. Al-Ali,
C. V. van Helden-Meeuwsen,
N. Maria,
J. Tarn,
D. Lendrem,
Marco W J Schreurs,
E. Steenwijk,
P. V. van Daele,
T. Both,
...
S. Bowman,
B. Griffiths,
W. Ng,
M. Versnel
|
6 |
2018 |
6
🐜
|
|
🐜
|
Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndrome
12 auth.
N. Maria,
E. Steenwijk,
A. IJpma,
C. V. van Helden-Meeuwsen,
P. Vogelsang,
W. Beumer,
...
Z. Brkić,
P. V. van Daele,
P. M. van Hagen,
P. J. van der Spek,
H. Drexhage,
M. Versnel
|
6 |
2016 |
6
🐜
|
|
🐬
|
Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial
I. Bodewes,
J. Gottenberg,
C. V. van Helden-Meeuwsen,
X. Mariette,
M. Versnel
|
5 |
2019 |
5
🐬
|
|
🐜
|
Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3‐Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon‐Positive Primary Sjögren's Syndrome
15 auth.
N. Maria,
C. V. van Helden-Meeuwsen,
Z. Brkić,
S. Paulissen,
E. Steenwijk,
V. Dalm,
P. V. van Daele,
P. Martin van Hagen,
F. Kroese,
J. V. van Roon,
...
A. Harkin,
W. Dik,
H. Drexhage,
E. Lubberts,
M. Versnel
|
5 |
2016 |
5
🐜
|
|
🐜
|
TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.
11 auth.
I. Bodewes,
E. Huijser,
C. V. van Helden-Meeuwsen,
L. Tas,
R. Huizinga,
V. Dalm,
...
P. M. van Hagen,
N. Groot,
S. Kamphuis,
P. V. van Daele,
M. Versnel
|
5 |
2018 |
5
🐜
|
|
🐜
|
NOD mice have a severly impaired ability to recruit leukocytes into sites of inflammation
8 auth.
G. Bouma,
T. Nikolić,
J. Coppens,
C. V. van Helden-Meeuwsen,
P. Leenen,
H. Drexhage,
...
S. Sozzani,
M. Versnel
|
5 |
2005 |
5
🐜
|
